Kornimate/medical-research-clean huggingface dataset:
the effect of leptin a-200, caffeine/ephedrine and their combination upon weight loss and body composition in man

Conditions: Obesity

Summary: the purpose of this study is to compare three treatments to see which causes the most weight loss, fat loss, loss of stomach fat and improvement in blood tests like cholesterol.

three treatments are compared to see which causes the most weight loss, fat loss, loss of stomach fat and improvement in blood tests like cholesterol. 1) leptin a-200 injections daily with 2 inactive pills taken three times a day, 2) caffeine with ephedrine pills taken 3 times a day with an inactive injection daily and 3) both leptin a-200 injections daily and caffeine with ephedrine pills taken three times a day.

Eligibility criteria:
inclusion criteria: * you are healthy. * you are not pregnant or nursing. * you are between 18 and 60 years of age. * you have a body mass index, calculated from your height and weight, of 30 to 40 kg/m2. exclusion criteria: * you take chronic medications except hormone replacement or contraception. * you are a woman and are unwilling to use effective contraception during the trial. * you have blood pressure higher than 150/90. * you have heart disease. * you have urinary symptoms from an enlarged prostate. * you have gained or lost more than 10 pounds in the last 6 months. * you have used a monoamine oxidase inhibitor medication in the last month. * you have high or low thyroid function that has not been controlled in the normal range for at least 2 months. * you have heart disease or a history of stroke. * you have a known sensitivity to e. coli or e. coli derived products.
efficacy and safety of runzao zhiyang capsule to treat chronic eczema

Conditions: Chronic Eczema

Summary: the purpose of this study is to evaluate the efficacy and safety of runzao zhiyang capsule in treating chronic eczema.

polygoni multiflori preparata, dried rehmannia root, mulberry leaf, sophora flavescens, honghuoma, for skin itching, acne, constipation due to blood vacuity and wind-dryness, also used in clinical treatment of eczema. the purpose of this study is to evaluate the efficacy and safety of runzao zhiyang capsule in treating chronic eczema.

Eligibility criteria:
inclusion criteria: * consistent with diagnostic criteria for chronic eczema(referring to "the chinese eczema diagnosis and treatment guidelines" in 2011); * investigator global assessment (iga) score was 2 or 3; * the skin lesions were localized, hypertrophy and dry, and the affected skin area was 3%\~10% of body surface area (estimated by palm method); the diameter of target lesions was 2\~10cm and located in the limbs or trunk. * the course of chronic eczema is more than 6 months; * age 18 to 70, males or females; * the subjects obtain informed consent, participated the trial voluntarily. procedure to obtain informed consent is in accordance with the provisions of good clinical practise(gcp). exclusion criteria: * subjects with acute eczema, subacute eczema, universal eczema, special type of eczema; * subjects used corticosteroids, immunosuppressive agents and ultraviolet irradiation in 4 weeks prior to the enrollment; * subjects were treated with antihistamine and topical drugs in 2 weeks; * women in pregnancy, lactation, or planned pregnancy during the test; * comorbid with severe primary heart, liver, lung, kidney, blood disease, diabetes, thyroid disease or a serious disease affecting survival, such as cancer or hiv / aids; * subjects were allergic to test drug ingredients; * subjects could not give full informed consent because of mental and behavioral disorders; * suspected or identified with a history of alcohol or drug abuse; * have other diseases or conditions which may reduce the possibility of enrollment or complicate the recruiting process based on the investigator judgment. for example, working environment changed frequently led to easily lost follow-up; * have been or currently enrolled in other clinical trials within 3 months.

Keywords: chronic eczema efficacy and safety runzao zhiyang capsule
comparative study of physiological and cerebrovascular reactivity in depression, at the three phases of emotion

Conditions: Major Depressive Disorder

Summary: the main objective is to compare the physiological reactivity (heart and respiratory rates, galvanic skin response, cerebral perfusion, and startle) in the three phases of emotion between depressive subjects, subjects remitted from depression and control subjects.


Eligibility criteria:
inclusion criteria: * female between 18 and 55 * informed consent form signed * affiliated to a medical insurance * visual and hearing abilities suitable for exams * for the depressive group (group d): major depressive disorder according to the dsm-iv criteria as evaluated by the mini test and madrs score ≥22 * for the depressive patients in remission's group (group r) : matched on age, at least 1 history of major depressive disorder in the last 10 years and solved for more than 6 months, and madrs score \< 9 * for the control subjects (group t) : matched on age, no psychiatric history, madrs score \< 9 exclusion criteria: * psychotic disorder, bipolar disorder, addiction, suspected dementia (mmse\<25) * current betablockers or neuroleptics treatment * any current organic unstable pathology * history of serious cardiovascular disease (coronary syndrome, cardiac arrythmia, etc.) * smoking \> 10 py * history of serious neurologic disease (stroke, cerebral tumour, serious cranial trauma, headache, ...) * contra-indication to mri * uncorrected vision or audition troubles * patient under juridic protection * pregnancy, lactating or female without reliable contraception

Keywords: major depressive disorder cerebrovascular reactivity emotional reactivity
registry study of pharmacotherapy and clinical outcomes in elderly patients with coronary heart disease (pharm-ageing)

Conditions: Elderly Patients; Coronary Heart Disease; Drug Therapy; Clinical Outcomes

Summary: a registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease


Eligibility criteria:
inclusion criteria: * informed consent has been signed * patients diagnosed in our hospital with coronary heart disease * age ≥65 years exclusion criteria: * severe lack of important information such as history of previous medication, history of previous disease, history of surgery. * mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.
identify training strategies for progressing exoskeleton users towards everyday functional ambulation

Conditions: Spinal Cord Injury

Summary: many people with spinal cord injury are no longer able to walk and must use wheelchairs for mobility. these individuals experience greater rates of depression and lower quality of life. many of these individuals express a strong desire to walk again, and report many psychosocial benefits to being eye to eye with peers in social interactions. additionally, wheelchairs allow only limited community access, creating an additional obstacle to seeking out meaningful social roles in the community. currently, there is new technology called robotic exoskeletons that would allow people with spinal cord injury to walk. these robotic exoskeletons also allow for curb, ramp, and stair negotiation, which are critical to community access. current research has examined training with robotic exoskeletons indoors over level surfaces in clinical settings. this study will examine the potential for everyday use, including ramps, stairs, curbs and indoor and outdoor use.


Eligibility criteria:
inclusion criteria: * sci level c6-8, t1-t12; l1-l5 incomplete or complete * be able to physically fit into the exoskeleton device; * be able to tolerate upright standing for a minimum of 30 minutes; * have sufficient upper body strength to use forearm crutches in standing and during ambulation (including full triceps strength and good hand function); * have hip, knee, and ankle range of motion within normal functional limits of walking; * have the ability to follow directions and demonstrate learning capacity; * ability to understand and the willingness to sign a written informed consent. exclusion criteria: * cervical level sci above c6 * history of severe osteoporosis; * weight above 220 pounds; * femur length above 47 cm or below 36 cm * joint contractures at the hip, knee, or ankle that limit normal range of motion (rom) during ambulation; * cognitive and/or communication disability (e.g. due to brain injury); * history of significant problems with skin break down or current skin break down; * any medical issue that precludes full weight bearing and ambulation (e.g. orthopedic injuries, pain, severe spasticity); * pregnancy; * cardiovascular conditions such as history of heart attack, high blood pressure, pacemaker, arrhythmia, heart failure, or stroke.

Keywords: spinal cord injury exoskeleton ambulation walking robotics
appendicitis with medical treatment

Conditions: Appendicitis

Summary: prospective study to collect data of patients with appendicitis, not receiving operation

using ultrasound to follow up the resolution of acute appendicitis

Eligibility criteria:
inclusion criteria:patients with appendicitis, not receiving operation - exclusion criteria:nil -

Keywords: appendicitis
mental health and resilience in emerging adulthood

Conditions: Depression; Anxiety; Personality Disorders

Summary: the purpose of this study is to examine differences in selected psychiatric/psychological variables between a sample of unemployed young adults who have dropped out of high school and a sample of college students.


Eligibility criteria:
inclusion criteria: * subjects 18-25 years old who have dropped out of school and who are currently unemployed exclusion criteria: -
cardiovascular health promotion among african-americans by faith!

Conditions: Cardiovascular Diseases; Prevention; Physical Activity; Diet Modification; Diabetes; Hypertension; High Cholesterol; Pre Diabetes; Smoking Cessation; Obesity

Summary: given the importance of healthy lifestyle practices to cardiovascular disease (cvd) prevention and the utility of church-based interventions in african-american adults, the investigators developed a theory-informed, strategically-planned, health and wellness intervention with rochester, minnesota (mn) and twin cities area (minneapolis, st. paul, mn) churches with predominately african-american congregations. the objective of the study was to partner with churches to implement a multi-component, health education program through the use of core educational sessions delivered through a digital-application accessible on demand via interactive access on computer tablets and the internet. the overarching goal was to increase the awareness and critical importance of healthy lifestyles for cvd prevention and provide support for behavior change.


Eligibility criteria:
inclusion criteria: * basic internet navigation skills, at least weekly internet access, active email address, minimal fruit/vegetable intake (\<5 servings/day), no regular physical activity program (\< 30 minutes/d of moderate physical activity), able to engage in moderate physical activity (no restrictions) exclusion criteria: * diagnosis of a serious medical condition or disability that would make participation difficult (i.e. visual or hearing impairment, mental disability that would preclude independent use of the app)
a pharmacokinetic evaluation of metformin in relation to the polymorphism a270s in healthy caucasian volunteers

Conditions: Metformin; Organic Cation Transporter 2; Polymorphism,Single Nucleotide

Summary: the aim of the study is to evaluate the pharmacokinetics of metformin in healthy caucasians volunteers with and without the polymorphism a270s in oct2,thus the study hypothesis is that renal clearance of metformin is affected in caucasian with the known single nucleotide polymorphisms a270s in oct2.


Eligibility criteria:
inclusion criteria: * healthy volunteers * written consent * rs316019 genotyped * age 18-65 years old exclusion criteria: * daily medication * alcohol abuse * pregnancy * breastfeeding

Keywords: diabetes mellitus, type 2 metabolic clearance rate pharmacokinetics pharmacogenetics
a comparison of strict glucose control with usual care at the time of islet cell transplantation

Conditions: Diabetes Mellitus, Type 1; Islet Transplantation

Summary: islet transplants for those with type 1 diabetes have enabled many to initially eliminate insulin, however, only a fraction of the transplanted cells typically survive and the functioning of these decrease over time. as a result, most patients will eventually require some insulin. currently, the cause of this poor survival and decrease in function is not understood; although previous research has demonstrated that even a slightly elevated level of blood glucose can impair islet function. this study will determine if strict blood glucose control at the time of islet transplantation, when the cells are the most fragile, will improve the survival and functioning of transplanted islet cells three months after transplantation.


Eligibility criteria:
inclusion criteria: * 18 to 65 years of age * more than 5 years since diagnosis of diabetes * c-peptide negative exclusion criteria: * ischemic heart disease * previous transplant * recurrent infections * malignancy (except basal or squamous skin cancer)
aggressiveness of care at the end of life in cancer patients

Conditions: Advanced Cancer

Summary: cancer is the commonest cause of death in singapore, and many cancer deaths occur in hospital. management of cancer patients is getting more complex with constant development of new drugs, interventional procedures and supportive measures. despite this, the majority of advanced cancer patients will die from their disease or related complications. there is a lack of data on the utilisation of health resources in advanced cancer patients in this country. in this study the investigators ask themselves how aggressive care was in the last 3 months of the patient's life. the investigators will be collecting data on specific cancer treatments, interventional procedures, and supportive measures.


Eligibility criteria:
inclusion criteria: * advanced cancer patients who passed away as an inpatient in nuh, under the department of haematology oncology. exclusion criteria: * patients with haematologic malignancies.

Keywords: advanced cancer patients dying in hospital receive aggressive cancer-specific therapy and supportive measures.
optimizing timing of rhpsma-7.3 (18f) for assessing site(s) of recurrent disease following radical prostatectomy

Conditions: Prostate Cancer

Summary: all men following radical prostatectomy (rp) at nyu langone health undergo routine prostate specific antigen (psa) testing in order to identify disease recurrence. by consensus, a bcr following rp occurs once the psa \> 0.2 ng/ml/ biochemical recurrence often develops years prior to clinical evidence of disease recurrence. early identification of the site(s) of disease recurrence enables early salvage intervention. men will be eligible for the study at the point in time their post-prostatectomy psa level first becomes \>0.2 ng/ml. only those patients with rhpsma-7.3 (18f) identifiable disease (local, nodal or systemic) will be offered salvage intervention per standard of care. all patients with a negative initial rhpsma-7.3 (18f) scan will undergo a second scan when the psa is \> 0,5 ng/ml or one year after the initial pet study. the salvage interventions will be at the discretion of the investigator. the study will compare the diagnostic yield of the first and second rhpsma-7.3 (18f) studies.


Eligibility criteria:
inclusion criteria: eligible patients will include all men between age 18 -100 years old,-that have had rp, at the first point in time the psa \> 0.2 ng/ml. exclusion criteria: * any contraindication for mri imaging. * prior allergic reaction to rhpsma-7.3 (18f). * patient refuses rhpsma-7.3 (18f) pet/mri.
platform trial for cryptococcal meningitis

Conditions: Hiv; Cryptococcal Meningitis

Summary: cryptococcal meningitis is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. even with antifungal therapy, mortality rates remain high, especially in low and middle income countries where the ongoing hiv/aids pandemic increases the risk of cryptococcosis among persons living with hiv infection. the combination of amphotericin and flucytosine (5-fc) has been the mainstay of therapy for the initial management of cryptococcal meningitis for 4 decades. indeed, the effective delivery of these first line therapy in africa can lower mortality to 25%. however, several challenges exist. first, even while 5-fc is included on the who list of essential medicines, the availability of 5-fc worldwide is limited. second, liposomal amphotericin (ambisome ®) is currently available from a single source supplier, creating risk. third, current therapies have substantial toxicity. lastly, with widespread agricultural fungicide use of azoles, the median fluconazole minimum inhibitory concentration (mic50 ) for cryptococcus has doubled since 2013. globally, new or improved antifungals are needed for cryptococcal meningitis, particularly those which have less toxicity, greater efficacy, a prolonged half-life, and minimal drug-drug interactions. as multiple new antifungal medicines are on the horizon, this platform trial utilizes a master protocol to investigate, multiple regimens using standardized eligibility criteria, standardized study schedule of events, and standardized contemporary endpoints.


Eligibility criteria:
inclusion criteria: * csf cryptococcal antigen (crag) positive meningitis * hiv positive * ability and willingness to provide informed consent * willing to receive protocol-specified lumbar punctures * age \>= 18 years * female participants of childbearing potential who are participating in sexual activity that could lead to pregnancy must agree to use reliable forms of contraception (duration will be indicated in each trial appendix). exclusion criteria: * received \>= 3 doses of antifungal therapy for meningitis treatment or \> 6mg/kg of liposomal amphotericin b cumulatively within prior 30 days * inability to take enteral (oral or nasogastric) medicine * cannot or unlikely to attend regular clinic visits * receiving chemotherapy or corticosteroids * receiving hemodialysis or known liver cirrhosis * suspected paradoxical immune reconstitution inflammatory syndrome (iris) * pregnancy or breastfeeding * previous administration of investigational study drug * any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments * trial appendix study-drug specific eligibility criteria
carbohydrate mouth rinse (small-sided soccer games)

Conditions: Performance; Soccer; Carbohydrate; Mental Fatigue; Technical Skill

Summary: the present study evaluated the influence of carbohydrate mouth-rinsing (cho- mr) and placebo (pla) conditions on the psychophysiological responses, kinematic profiles, and technical performance of young male soccer players in 4-small sided games (ssgs). the study participants were involved in a randomized, double-blind, repeated-measures design that employed 3 sessions (familiarization, chomr and pla) over fifteen days at a testing facility. participants took part in two test sessions one week apart. cho solution was a maltodextrin-based mixture containing 6.4% maltodextrin (protein ocean, türkiye). the pla solution consisted of pure water. both solutions were made indistinguishable by incorporating 50 mg of a non-calorific artificial sweetener and 50 mg og sucralose (fibrelle, türkiye). a 25-ml bolus of 6.4% maltodextrin solution was utilized in a pre-weighed plastic cup, with sucralose water tested as pla for each rinse solution.

the current study used a double-blind, randomized, and counterbalanced crossover design to compare the effects of chomr or pla on psychophysiological, kinematic responses and technical actions during 4-a-side ssgs. the study intervention programs lasted the same time of the day during separate training sessions in the in-season to avoid various chronobiological factors. the average temperature was 30 °c, with a relative humidity of 35% of the baseline assessments. second assessments were recorded that the average temperature was 31 °c with a 35% relative humidity. before the ssgs sessions, anthropometric characteristics were assessed. players also completed the yo-yo intermittent recovery test level 1 (yyirtl-1) to balance the groups and equally distribute players among ssgs teams based on maximal oxygen uptake ( 2max). the order of different ssgs (chomr or pla) and solutions (mr or pla) was determined by randomization (www.randomization.com). each ssgs was separated at least one week apart to minimize the potential negative impact of physical and psychological fatigue on game performance. continuous monitoring and recording of the heart rate (hr), rating of perceived exertion (rpe), enjoyment and mental fatigue (mf), kinematic responses, and technical actions were conducted during all ssgs. mood responses were assessed before and after each ssgs. uefa a licenced strength and conditioning coaches consistently implemented all ssgs sessions on an artificial soccer pitch with verbal coach encouragement.

Eligibility criteria:
inclusion criteria: * being healthy * male soccer players * willing to maintain the intervention for all sessions exclusion criteria: * being under 14 years old * having a chronic disease * contraindication for carbohydrate mouth-rinsing (cho-mr)

Keywords: game-based training carbohydrate game performance psychophysiological performance analysis
4 pillars toolkit for adolescent vaccination

Conditions: Adolescent HPV Vaccine; Adolescent Influenza Vaccine

Summary: the purpose of this study is to test whether or not the 4 pillars immunization toolkit increases adolescent vaccination rates, particularly influenza and human papillomavirus (hpv) but also tetanus, diphtheria and pertussis (tdap), and meningococcal conjugate (mcv) vaccination rates. the vaccines are all fda licensed vaccines and to be used according to national guidelines. the investigators will conduct a randomized cluster trial of this toolkit in diverse primary care practices with electronic medical records (emrs).

this intervention is a stratified randomized cluster trial in about 22 diverse primary care practices. these practices will be randomly assigned to be intervention or control sites to test this 4 pillars immunization toolkit intervention package of evidence-based techniques tailored to their practice structure and culture; the specialties are split between pediatric and family medicine practices. .

Eligibility criteria:
inclusion criteria: * for clinical sites: inclusion criterion includes 1. an appropriate adolescent population: e.g., adolescents aged 11 to 17 years 2. currently using an emr 3. having and keeping immunization data within a emr or registry. exclusion criteria: * for clinical sites: the exclusion criteria is consistent sop use for the vaccines being studied or known much higher than average immunization rates.

Keywords: influenza hpv tdap mcv vaccination adolescents